Abstracts tagged "gout"

Abstract Number: 2834 • 2019 ACR/ARP Annual Meeting
Assessing the Risk of Gout with Sodium Glucose Co-Transporter-2 Inhibitors: A Population-Based Cohort Study
Michael Fralick¹, Sarah Chen ², Elisabetta Patorno ³ and Seoyoung C. Kim ⁴, ¹Mount Sinai Hospital, University of Toronto, Toronto, ²Brigham and Women's Hospital and Harvard Medical School, Boston, ³Harvard University, Boston, ⁴Brigham and Women’s Hospital and Harvard Medical School, Boston
Background/Purpose: Hyperuricemia is common in patients with type 2 diabetes mellitus and is associated with an increased risk of gout. Sodium-glucose cotransporter 2 (SGLT2) inhibitors,…
Abstract Number: 1006 • 2018 ACR/ARHP Annual Meeting
Physical Activity at Lower Intensities Reduces Localized IL-1b in a Murine Model of Gout By Systemically Down-Regulating TLR2 Expression on Circulating Neutrophils and Suppressing CXCL1 Expression
Kyle Jablonski¹, Nicholas A. Young², Bianca Sandoval³, Ifeoma Okafor⁴, Emily Schwarz³, Caitlin Henry³, Peter Harb³, Anuradha Kalyanasundaram⁵, Wael Jarjour⁶ and Naomi Schlesinger⁷, ¹The Ohio State University Wexner Medical Center, Columbus, OH, ²Immunology and Rheumatology, The Ohio State University Wexner Medical Center, Columbus, OH, ³Rheumatology and Immunology, Columbus, OH, ⁴Rheumatology and Immunology, The Ohio State University Wexner Medical Center, Columbus, OH, ⁵Physiology and Cell Biology, The Ohio State University, Columbus, OH, ⁶Department of Rheumatology and Immunology, The Ohio State University Wexner Medical Center, Columbus, OH, ⁷Department of Medicine/Rheumatology Division, Rutgers- Robert Wood Johnson Medical School, New Brunswick, New Brunswick, NY
Background/Purpose: Exercise was originally believed to exacerbate inflammation in rheumatic disease, however, recent studies have shown that regular physical activity is anti-inflammatory. In gout, there…
Abstract Number: 1288 • 2018 ACR/ARHP Annual Meeting
Association between Musculoskeletal Ultrasonography and Bone Remodeling Markers and the Role of Ultrasonography on Monitoring Treatment Responsiveness in Patients with Gout and Hyperuricemia
Ya-dan Zou^1,2, Ya-nan Fei¹, Hui Gao³, Lin-feng Xie¹, Yu-chao Zhong¹ and Xuewu Zhang³, ¹Peking University People's Hospital, Beijing, China, ²Peking University International Hospital, Beijing, China, ³Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China
Background/Purpose: Musculoskeletal ultrasonography (US) is an invasive method to identify gout related bone damage, while Dickkopf-1 (DKK-1) and receptor activator of nuclear factor-κB ligand（RANKL）are bone…
Abstract Number: 2250 • 2018 ACR/ARHP Annual Meeting
Mitigation of Inflammation Induced By Monosodium Urate Crystals in Mice By Treatment with Svp-Rapamycin
Pallavi Kolte, Robert LaMothe, Joseph Ferrari, Sheldon Leung, Wesley DeHaan Ph.D., Earl Sands and Takashi Kei Kishimoto, Selecta Biosciences, Watertown, MA
Background/Purpose: Initiation of urate-lowering therapies is typically associated with an increase in gout flares due to mobilization of pro-inflammatory urate crystals. SEL-212 is a novel…
Abstract Number: 1030 • 2018 ACR/ARHP Annual Meeting
Parenteral Injection of Human Adipose-Derived Mesenchymal Stem Cells Attenuates Inflammation in an Acute Model of Gouty Arthritis
Juan Pablo Medina¹, Sandra Perez-Baos¹, Esperanza Naredo², Alberto Lopez-Reyes³, Gabriel Herrero-Beaumont⁴ and Raquel Largo⁴, ¹Joint and Bone Research Unit, IIS-Fundacion Jimenez Diaz UAM, Madrid, Spain, ²Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain, ³Synovial fluid analysis department, Instituto Nacional de Rehabilitación, Mexico City, Mexico, ⁴Bone and Joint Research Unit, Fundación Jiménez Díaz University Hospital & Health Research Institute, Madrid, Spain
Background/Purpose: The regenerative and immunomodulatory properties of Adipose-Derived Mesenchymal Stem Cells (ASCs) make them a potential therapeutic approach for the treatment of chronic inflammatory diseases,…
Abstract Number: 1289 • 2018 ACR/ARHP Annual Meeting
Immunosuppressant Use and Gout in the Prevalent Solid Organ Transplant Population
Andrew Milgroom¹, Mara Onita Lenco¹, Kevin Francis¹, Jeffrey D. Kent², Brian LaMoreaux³ and Brian F. Mandell⁴, ¹Trinity Partners, Waltham, MA, ²Medical Affairs, Horizon Pharma USA, Inc, Lake Forest, IL, ³Horizon Pharma USA, Inc, Lake Forest, IL, ⁴Rheumatology, Cleveland Clinic, Cleveland, OH
Background/Purpose: Gout is a frequent co-morbidity of solid organ transplant (SOT). Cyclosporine (CsA) is often cited as the main cause of gout in SOT, as…
Abstract Number: 2252 • 2018 ACR/ARHP Annual Meeting
Serum Urate Ant Its Clearance in Patients with Chronic Kidney Disease Under Peritoneal Dialysis
Claudia Diez¹, Javier Pérez-Contreras^1,2 and Mariano Andrés^1,3, ¹Departamento de Medicina Clínica, Universidad Miguel Hernández, Alicante, Spain, ²Servicio de Nefrología, Hospital General Universitario de Alicante-ISABIAL, Alicante, Spain, ³Hospital General Universitario de Alicante-ISABIAL, Alicante, Spain
Background/Purpose: Hyperuricemia and gout are common in patients with chronic kidney disease (CKD), some ultimately requiring replacement therapy. Serum urate (SU) levels appear to achieve…
Abstract Number: 1031 • 2018 ACR/ARHP Annual Meeting
Orally Administered Cherry Juice Inhibits Localized Nfκb Activity and Histopathological Infiltrates in a Murine Model of Gout
Nicholas A. Young¹, Peter Harb², Ifeoma Okafor³, Caitlin Henry², Emily Schwarz², Kyle Jablonski⁴, Bianca Sandoval², Wael Jarjour⁵ and Naomi Schlesinger⁶, ¹Immunology and Rheumatology, The Ohio State University Wexner Medical Center, Columbus, OH, ²Rheumatology and Immunology, Columbus, OH, ³Rheumatology and Immunology, The Ohio State University Wexner Medical Center, Columbus, OH, ⁴The Ohio State University Wexner Medical Center, Columbus, OH, ⁵Department of Rheumatology and Immunology, The Ohio State University Wexner Medical Center, Columbus, OH, ⁶Department of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ
Background/Purpose: Gout is caused by the inflammation induced from the precipitation of monosodium urate (MSU) crystals in joints and is the most common inflammatory arthritis…
Abstract Number: 1290 • 2018 ACR/ARHP Annual Meeting
Systemic Inflammation and Atherosclerosis in Patients with Gout. Results from the NOR-Gout Study
Silvia Rollefstad¹, Till Uhlig^2,3, Lars Fridtjof Karoliussen³, Hilde B. Hammer⁴ and Anne Grete Semb⁵, ¹Preventive Cardio-Rheuma clinic, Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²University of Oslo, Oslo, Norway, ³Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Dept. of Rheumtology, Diakonhjemmet Hospital, Oslo, Norway, ⁵Preventive Cardio-Rheuma clinic, Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
Systemic inflammation and atherosclerosis in patients with gout. Results from the NOR-Gout studyBackground/Purpose: The association between gout and cardiovascular disease (CVD) is well known, whereas…
Abstract Number: 2254 • 2018 ACR/ARHP Annual Meeting
Update of SEL-212 Phase 2 Clinical Data in Symptomatic Gout Patients: Svp-Rapamycin Combined with Pegadricase Mitigates Immunogenicity and Enables Sustained Reduction of Serum Uric Acid Levels, Low Rate of Gout Flares and Monthly Dosing
Earl Sands¹, Alan J. Kivitz², Wesley DeHaan Ph.D.¹, Lloyd Johnston¹ and Takashi Kei Kishimoto¹, ¹Selecta Biosciences, Watertown, MA, ²Altoona Center for Clinical Research, Duncansville, PA
Background/Purpose: Pegylated uricases are promising therapies for the treatment of severe chronic gout, but are limited by their immunogenicity. We have previously shown that synthetic…
Abstract Number: 1124 • 2018 ACR/ARHP Annual Meeting
Epidemiological Characteristics of Inpatient Admissions for Acute Inflammatory Gout Arthropathy and Factors Affecting Length of Stay: A National Level Study
Vagishwari Murugesan and Jennifer Tran, Internal Medicine, Medstar Washington Hospital Center, Washington, DC
Background/Purpose:Gout is a common cause of inflammatory arthritis due to accumulation of monosodium urate crystals in joints, bones and soft tissues. The aim of the…
Abstract Number: 1294 • 2018 ACR/ARHP Annual Meeting
Initial Phase 2 Clinical Data of SEL-212 in Symptomatic Gout Patients: Monthly Dosing of a Pegylated Uricase (Pegadricase) with Svp-Rapamycin Enables Sustained Reduction of Acute Gout Flares
Rehan Azeem¹, Alan J. Kivitz², Earl Sands¹, Wesley DeHaan Ph.D.³, Lloyd Johnston³ and Takashi Kei Kishimoto³, ¹Selecta Biosciences, Inc, Watertown, MA, ²Altoona Center for Clinical Research, Duncansville, PA, ³Selecta Biosciences, Watertown, MA
Background/Purpose: Pegylated uricases are therapies for treatment of severe chronic gout, particularly for rapid tophi resolution. However, uricases are limited by induction of anti-drug antibodies…
Abstract Number: 2255 • 2018 ACR/ARHP Annual Meeting
Increased Cost Burden in an Early Diagnosed Cohort of Uncontrolled Versus Controlled Gout: Analysis of a Large US Payer Database
Brian LaMoreaux¹, Megan Francis-Sedlak² and Robert J Holt², ¹Horizon Pharma USA, Inc, Lake Forest, IL, ²Horizon Pharma USA, Inc., Lake Forest, IL
Background/Purpose: Gout is a progressive systemic inflammatory disease that is widely prevalent, estimated to effect 3.9% or 8.3 million people of the United State (US)…
Abstract Number: 1131 • 2018 ACR/ARHP Annual Meeting
The Prevalence and Incidence of Gout, Its Associated Comorbidities and Treatment Pattern: An Epidemiological Study from Germany
Uta Kiltz¹, Fernando Perez-Ruiz², Till Uhlig³, Tim L. Jansen⁴, Ravichandra Karra Gurunath⁵, Niklas Schmedt⁶, Wolfgang Galetzka⁶, Gudula Petersen⁵, Tonio Schoenfelder⁷ and Anne-Kathrin Tausche⁸, ¹Rheumazentrum Ruhrgebiet, Herne, and Ruhr-University, Bochum, Herne, Germany, ²BioCruces Health Research Institute, Barakaldo, Spain, ³University of Oslo, Oslo, Norway, ⁴Rheumatology, VieCuri Medical Centre, Venlo, Netherlands, ⁵Grünenthal GmbH, Aachen, Germany, ⁶InGef – Institute for Applied Health Research, Berlin, Germany, ⁷Institute for Applied Health Services Research, Berlin, Germany, ⁸Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden, Dresden, Germany
Background/Purpose: The most common type of inflammatory arthritis in Germany is gout, however the last epidemiological study was done a decade ago (Annemanns, 2007). This…
Abstract Number: 1296 • 2018 ACR/ARHP Annual Meeting
A Novel Potent and Selective Urate Transporter 1 Inhibitor, NC-2700, with pH-Raising Effect on Low Urinary pH
Masuharu Hirano¹, Takafumi Muto¹, Toshitake Hirai², Promsuk Jutabha³, Naohiko Anzai⁴, Toru Horie⁵, Hitoshi Endou⁶ and Tomio Yamakawa⁷, ¹Discovery Research Laboratories, Nippon Chemiphar Co., Ltd., Misato, Saitama Prefecture, Japan, ²Nippon Chemiphar Co., Ltd., Misato, Saitama Prefecture, Japan, ³Dokkyo Medical University School of Medicine, Tochigi, Japan, ⁴Chiba University Graduate School of Medicine, Chiba, Japan, ⁵Dethree Res Lab Inc., Tsukuba, Japan, ⁶J-Pharma Co., Ltd., Yokohama, Japan, ⁷Discovery Research Laboratories, Nippon Chemiphar Co., Ltd., Misato, Saitama prefecture, Japan
Background/Purpose: In most patients with gout, renal underexcretion of uric acid is the main mechanism for hyperuricemia. However, for the risk of uric acid kidney…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].